Sign up to access historical data
Similar companies
| Company | Est. Transaction Value | |
|---|---|---|
 |
PfizerPFE |
-$87,000 |
 |
AstrazenecaAZN |
$32,000 |
 |
Johnson & JohnsonJNJ |
-$230,000 |
 |
ModernaMRNA |
$16,000 |
 |
AbbVieABBV |
$88,000 |
Trades by US Politicians
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Gilbert Cisneros | Dec 19, 2025 | Buy | $1K - $15K |
| Julie Johnson | Dec 18, 2025 | Sell | $1K - $15K |
| Julie Johnson | Nov 13, 2025 | Sell | $1K - $15K |
| Gilbert Cisneros | Nov 12, 2025 | Buy | $1K - $15K |
| Gilbert Cisneros | Oct 9, 2025 | Sell | $1K - $15K |
| Julie Johnson | Aug 14, 2025 | Sell | $1K - $15K |
| Virginia Foxx | Jun 24, 2025 | Sell | $1K - $15K |
| Jefferson Shreve | May 12, 2025 | Sell | $15K - $50K |
| Julia Letlow | Apr 28, 2025 | Sell | $1K - $15K |
| Julie Johnson | Apr 1, 2025 | Sell | $1K - $15K |
| Greg Landsman | Mar 27, 2025 | Sell | $1K - $15K |
| Julie Johnson | Jan 15, 2025 | Buy | $1K - $15K |
| Virginia Foxx | Dec 6, 2024 | Buy | $1K - $15K |
| Valerie Hoyle | Oct 29, 2024 | Buy | $1K - $15K |
| Julia Letlow | Oct 23, 2024 | Buy | $1K - $15K |
| Rohit Khanna Democrat | May 29, 2024 | Sell | $15K - $50K |
| Rohit Khanna Democrat | May 28, 2024 | Sell | $15K - $50K |
| Rohit Khanna Democrat | Apr 26, 2024 | Sell | $1K - $15K |
| Rohit Khanna Democrat | Apr 26, 2024 | Sell | $1K - $15K |
| Rohit Khanna Democrat | Apr 26, 2024 | Buy | $1K - $15K |
| Thomas Tuberville Republican | Apr 3, 2024 | Sell | $1K - $15K |
| Rohit Khanna Democrat | Mar 25, 2024 | Buy | $15K - $50K |
| Rohit Khanna Democrat | Feb 13, 2024 | Buy | $15K - $50K |
| Rohit Khanna Democrat | Feb 13, 2024 | Sell | $1K - $15K |
FAQ - Congress Trading
Gilbert Cisneros purchased Bristol-Myers Squibb shares most recently on December 19, 2025.
Rohit Khanna has bought the most BMY stock in the last 2 years, with an estimated value of $73,000.
Rohit Khanna has sold the most BMY stock in the last 2 years, with an estimated value of $89,000.
The net value of trades by US politicians for Bristol-Myers Squibb in the last 2 years is negative, amounting to -$73,000. This suggests that US politicians do not believe in the success of the company for various reasons.
Over the last 2 years, insider transactions for Bristol-Myers Squibb have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering politicians might have insights or reasons not immediately apparent to the public.
Monitoring US politicians' stock trades is valuable because they may have inside information about upcoming policies that could affect stock values, providing investors with valuable clues for making informed decisions.
